Evidence map›Paper›PMID 41219827›Full record

ArticleJournal of cheminformatics2025

C2PO: an ML-powered optimizer of the membrane permeability of cyclic peptides through chemical modification.

Roy Aerts, Joris Tavernier, Alan Kerstjens, Mazen Ahmad, Jose Carlos Gómez-Tamayo, Gary Tresadern, Hans De Winter

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Roy Aerts *Laboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitslaan 1, Wilrijk, 2610, Antwerp, Belgium.
Joris Tavernier *Open Analytics NV, Jupiterstraat 20, 2600, Antwerp, Belgium.
Alan KerstjensHyle, Antwerp, Belgium.
Mazen AhmadIn Silico Discovery, Janssen Research & Development, Janssen Pharmaceutica N. V., Turnhoutseweg 30, B-2340, Beerse, Belgium.
Jose Carlos Gómez-TamayoIn Silico Discovery, Janssen Research & Development, Janssen Pharmaceutica N. V., Turnhoutseweg 30, B-2340, Beerse, Belgium.
Gary TresadernIn Silico Discovery, Janssen Research & Development, Janssen Pharmaceutica N. V., Turnhoutseweg 30, B-2340, Beerse, Belgium.
Hans De WinterLaboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitslaan 1, Wilrijk, 2610, Antwerp, Belgium. hans.dewinter@uantwerpen.be.

Funding

Agentschap Innoveren en Ondernemen HBC.2021.112
6 · The paper itself

Abstract

Peptide drug development is currently receiving due attention as a modality between small and large molecules. Therapeutic peptides represent an opportunity to achieve high potency, selectivity, and reach intracellular targets. A new era in the development of therapeutic peptides emerged with the arrival of cyclic peptides which avoid the limitations of parenteral administration via achieving sufficient oral bioavailability. However, improving the membrane permeability of cyclic peptides remains one of the principal bottlenecks. Here, we introduce a deep learning regression model of cyclic peptide membrane permeability based on publicly available data. The model starts with a chemical structure and goes beyond the limited vocabulary language models to generalize to monomers beyond the ones in the training dataset. Moreover, we introduce an efficient estimator2generative wrapper to enable using the model in direct molecular optimization of membrane permeability via chemical modification. We name our application C2PO (Cyclic Peptide Permeability Optimizer). Lastly, we demonstrate how a molecule correction tool can be used to limit the presence of unfamiliar chemistry in the generated molecules.Scientific contribution: We provide an ML-driven optimizer application, named C2PO, that returns structurally modified cyclic peptides with an improved membrane permeability, one of the pivotal tasks in drug discovery and development. C2PO is a first-in-class application for cyclic peptide permeability amelioration, in that it converts a ML model into a generative optimizer of chemical structures. Additionally, through demonstration we incentivize the usage of an automated post-correction tool with a chemistry reference library to correct strange chemistry outputs from C2PO, a known issue for ML-generated chemical structures.

Identifiers

PMID41219827
PMCPMC12606850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.